İbrahim KARABULUT, Abdullah ERDOĞAN, Ercüment KESKİN

Transitional cell carcinoma of the bladder in young adult patients

Aim: Transitional cell carcinoma of the bladder (TCC) mostly affects the middle and old population as in other cancers. We aimed to present the results and clinical behaviors of patients treated with bladder TCC under the age of 40 years.Material and Methods: Fifteen patients who were admitted to our clinic between 2005 and 2019 and diagnosed as TCC were evaluated retrospectively. Demographic characteristics, initial and follow-up transurethral resection pathologies, intravesical treatment and follow-up periods were evaluated. All patients underwent transurethral resection after ultrasonography (USG) and cystoscopy examination.Results: The most common complaint was macroscopic hematuria (n:12.80%).Smoking rate was 66% (n:10). The mean age of the patients was 32.4 (19-39). Male / female ratio was 13/2. The mean follow-up period was 55 weeks. Ten patients (66%) had single focus and five (34%) had multiple focus tumors. In 10 patients, the tumor pathology TaG1, TaG3 in 3, T1G1 in one and T1G3 in one patient were reported.4 patients received intravesical chemotherapy and four patients underwent intravesical immunotherapy (BCG). The recurrence rate was 53% (n:8) and the rate of pro- gression was 13% (n:2) (TaG1-T1G3). None of the patients progressed to T2 disease.Conclusuion: Bladder TCC under 40 years of age usually presents as TaG1. Survival rates are high if follow-up and treatment protocols are followed. It should be kept in mind that there may be bladder tumors in young adult patients regardless of age.

PDF

___

1. Johnson DE and Hillis S. Carcinoma of the bladder in patients less than 40 years old. J Urol 1978;120:172-2. Wan J and Grossman HB. Bladder carcinoma in patients age 40 years or younger. Cancer 1989;64:178. 2. Loehrer P, Einhom LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic ürothelial carcinoma: a Cooperative Group, Study. J Clin Oncol 1992;10:1066-73.
3. Madrid Garcia FJ, Parra Muntaner L, Rivas Escudero JA, et al. Transitional cell bladder carcinoma in patients younger than 40 years of age. Arch Esp Urol 1998;991-4.
4. Messing EM. Urothelial tumors of the bladder. In Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA eds, Campbell- Walsh Urology, Ninth Edition, Chapter 2423-2511.
5. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer Survival and Incidence from the Surveillance, Epidemiology, and End Results (SEER) Program. The Oncologist 2003; 8:541-2.
6. Hong SJ, Cho KS, Han M, et al. Nomograms for prediction of disease recurrence in patients with primary Ta, T1 transitional cell carcinoma of the bladder. J Korean Med Sci 2008;23:428-33.
7. Bandis SH, Muray T, Borden S. Cancer statistics. Ca Cancer J Clin 1999;49:8-31
8. Jemal A, Siegel R, Ward E, Cancer Statistics, 2009 CA Cancer J Clin 2009;59:225-49.
9. Hayne 0, Arya M, Quinn Mj, et al. Current trends in bladder cancer in England and Wales. J Urol 2004;172:1051-5.
10. Bandis SH, Muray T, Borden S. Cancer statistics. Ca Cancer J Clin 1999;49:8-31.
11. Hendricksen K, Witjes JA. Treatment of intermediaterisk non-muscle-invasive bladder cancer (NMIBC). Eur Urol 2007;6:800-808.
12. Aydın S, Yılmaz Y, Özen S, ET AL. 20 yaşında görülen değişici epitel hücreli mesane tümörü olgusu. Van Tıp Dergisi 2001;8:102-4.
13. Aboutaieb R, Dakir M, Sarrf I, el Moussaoui A, Bennani S, el Mrini M et al. Bladder tumors in young patients. Prog Urol 1998;8:43-6.
14. Özbey I, Aksoy Y, Bicgi O, et al. Transitional cell carcinoma of the bladder in patients under 40 years of age. Int Urol Nephrol 1999;31:655-9.
15. Ikeda I, Terao T, Nakagomi K, et al. Recurrent transitional cell carcinoma of the bladder in a young woman: report of a case. Hinyokika Kiyo 1992;38:1261-3.
16. Laurenti C, De Dominicis C, Mattioli D, et al. Transitional cell neoplasm of the bladder in childhood: presentation of a clinical case. Arch Esp Urol 1993;46:51-4.
17. Yarmohammadi A, Ahmadnia H, Zare M. Transitional cell carcinoma in children: Report of a case and review of the literature. Urology Journal 2005;2:120-1.
18. Ali Çift, Hacı Polat, Mehmet Özgür Yücel, ve ark. 20 yaş ve altında mesane tümörü: 3 Olgu sunumu. The New Journal of Urology 2017;12:52-55.
19. Inagaki T, Nagata M, Kaneko M, et al. Carcino sarcoma with rhabdoid features of the urinary bladder in a 2-year-old girl: possible histogenesis of stem cell origin. Pathol Int 2000;50:973-8.
20. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009 CA Cancer J Clin 2009;59:225-249. 2
21. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al.Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.Eur Urol 2006;49:466-4.
22. Linn JF, Sesterhann I, Mostofi FK, et al. The molecular characteristics of bladder cancer in young patients. J Urol 1998;159:1493.
23. Wan J, Grosman HB. Bladder carcinoma in patients age 40 years or younger. Cancer 1989;64:178.
24. Irkılata HC, Goktas S, Coban H, at al. Characteristics of transitional cell carcinoma of the bladder in young adults. Turkish J Urology 2006;32:305-8.
25. Cole P, Hoover R, Friedell GH. Occupation and cancer of the lower urinary tract. Cancer 1972;29:1250.
26. Case RAM, Hosker ME, McDonald DB, et al. Tumors of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. Br J Ind Med 1954;11:75.
27. Alivizatos G, Dimopoulou I, Mitropoulos D, et al. . Bladder cancer in a young girl with systemic lupus erythematosus treated with cyclophosphamide. Acta Urol Belg 1991;59:133-7.
28. Babjuk M, Burger M, Comperat E, et al. EAU Guidelines on Non- muscle- invasive Bladder Cancer (TaT1 and CIS), 2017.